DNM3 Gene Deletion Study

Overview

About this study

The purpose of this study is to characterize the phenotype of DNM3 gene deletion through analysis of clinical data on a family with a DNM3 loss of function gene deletion, and comparison with published information to determine the clinical implications of haploinsufficiency of DNM3.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Individuals tested through the Cytogenetics laboratory  with a chromosome 1q24.3 deletion

Exclusion Criteria: 

  • None

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Linda Baughn, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions